Cargando…
Pharmacokinetics and Pharmacodynamics of Ruxolitinib: A Review
BACKGROUND AND OBJECTIVE: Ruxolitinib is a tyrosine kinase inhibitor targeting the Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathways. Ruxolitinib is used to treat myelofibrosis, polycythemia vera and steroid-refractory graft-versus-host disease in the setting of...
Autores principales: | Appeldoorn, T. Y. J., Munnink, T. H. Oude, Morsink, L. M., Hooge, M. N. Lub-de, Touw, D. J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064968/ https://www.ncbi.nlm.nih.gov/pubmed/37000342 http://dx.doi.org/10.1007/s40262-023-01225-7 |
Ejemplares similares
-
Pharmacokinetic Boosting of Kinase Inhibitors
por: Westra, Niels, et al.
Publicado: (2023) -
Pharmacokinetics and Target Attainment of Antimicrobial Drugs Throughout Pregnancy: Part I—Penicillins
por: Hesse, M. R., et al.
Publicado: (2023) -
The Pharmacokinetics and Target Attainment of Antimicrobial Drugs Throughout Pregnancy: Part III Non-penicillin and Non-cephalosporin Drugs
por: Groen, F., et al.
Publicado: (2023) -
The Effect of Pregnancy and Inflammatory Bowel Disease on the Pharmacokinetics of Drugs Related to Inflammatory Bowel Disease—A Systematic Literature Review
por: Wiersma, Thomas K., et al.
Publicado: (2022) -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Coadministered Ruxolitinib and Artemether-Lumefantrine in Healthy Adults
por: Chughlay, M. Farouk, et al.
Publicado: (2022)